| Name | Title | Contact Details |
|---|
Inscripta is a gene-editing technology company dedicated to creating the tools needed to revolutionize how we feed, fuel, and heal humanity.
Epirium Bio is a clinical-stage biopharmaceutical company developing therapeutics that promote mitochondrial biogenesis and function through a novel mechanism of action discovered by the company.
PathAI is the world`s leading PathAI`s mission is to advance medicine with intelligent pathology. PathAI`s platform provides end-to-end data-driven pathology analysis, resulting in fast, accurate and standardized pathologic diagnoses.
Renalytix plc (NASDAQ: RNLX) (LSE: RENX) is the global founder and leader in the new field of bioprognosisTM for kidney health. The company has engineered a new solution that successfully enables early-stage chronic kidney disease, progression risk assessment. The Company`s lead product, KidneyIntelX, has been granted Breakthrough Designation by the U.S. Food and Drug Administration and is designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery.
Biovista is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.